瑞普生物 reported revenue of ¥1.72B for the period ended 2026-06-30, +0.8% year on year. Net income was ¥0.22B, a 12.9% net margin on a 39.7% gross margin. The largest revenue line is 动保业务 at 75% of the total. Free cash flow for the period was ¥0.13B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.72B | +0.8% |
| Gross profit | ¥0.68B | — |
| Operating income | ¥0.24B | — |
| Net income | ¥0.22B | -18.4% |
| Gross margin | 39.7% | Net margin 12.9% |
| Revenue Q/Q | +8.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 动保业务 | ¥1.29B | 75.0% |
| 宠物供应链 | ¥0.43B | 25.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.04B | 60.3% |
| R&D | ¥0.11B | 6.2% |
| SG&A | ¥0.31B | 17.9% |
| Tax & other | ¥0.02B | 1.1% |
| Item | Amount |
|---|---|
| Total assets | ¥7.81B |
| Total liabilities | ¥2.69B |
| Shareholders' equity | ¥5.12B |
| Equity / assets | 65.6% |
| Operating cash flow | ¥0.18B |
| Capital expenditure | ¥0.05B |
| Free cash flow | ¥0.13B |
| Cash conversion (OCF / net income) | 87% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
经纬辉开 ・ 阳谷华泰 ・ ST亚光 ・ 聆达股份 ・ 锐奇股份 ・ 银河磁体 ・ 锦富技术 ・ 泰胜风能 ・ 新国都 ・ 英唐智控 ・ 青松股份 ・ 华策影视
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies